bioAffinity Technologies reports Q2 2026 CyPath Lung sales up >200% YoY, record quarter

bioAffinity Technologies, Inc.

Q2 2026 CyPath Lung sales volume >200% YoY and >30% over Q1 2026.
Nearly 3,000 tests performed since commercial launch.
155% increase in physician offices ordering CyPath Lung vs Q2 2025.
Company expects to report Q2 2026 financial results in August.
Initiatives include longitudinal study, oncology expansion, asthma/COPD tests.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.